Effects of apelin and vascular endothelial growth factor on central retinal vein occlusion in monkey eyes intravitreally injected with bevacizumab: A preliminary study

Molecular Vision

Volumn 17, Issue , 2011, Pages 1044-1055

  Zhao, Tong ^a   Lu, Qiang ^a   Tao, Yong ^a   Liang, Xiao Ying ^a   Wang, Kai ^a   Jiang, Yan Rong ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APELIN; BEVACIZUMAB; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CHOROID; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; ENUCLEATION; FLUORESCENCE IMAGING; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IRIS; LASER COAGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETINA; RETINA NEOVASCULARIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACACA MULATTA; RETINAL VEIN; RETINAL VEIN OCCLUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 79955618347     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Arevalo JF, Garcia RA, Wu L, Rodriguez FJ, Dalma-Weiszhausz J, Quiroz-Mercado H, Morales-Canton V, Roca JA, Berrocal MH, Graue-Wiechers F, Robledo V, Pan-American Collaborative Retina Study Group. Radial optic neurotomy for central retinal vein occlusion: results of the Pan-American Collaborative Retina Study Group (PACORES). Retina 2008; 28:1044-1052. [PMID: 18779709]
2. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 1997; 115:486-491. [PMID: 9109757]
3. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26:279-284. [PMID: 16508427]
4. Wang L, Song H. Effects of repeated injection of intravitreal triamcinolone on macular oedema in central retinal vein occlusion. Acta Ophthalmol 2009; 87:285-289. [PMID: 18507724]
5. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW. Inhibition of vascularendothelial growth factor prevents retinal ischemiaassociatediris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114:66-71. [PMID: 8540853]
6. Gregori NZ, Gaitan J, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE, Schwartz SG, Lee WH, Murray TG. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina 2008; 28:1325-1337. [PMID: 19430392]
7. Hou J, Tao Y, Jiang YR, Li XX, Gao L. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study. Chin Med J (Engl) 2009; 122:2695-2699. [PMID: 19951598]
8. Jiang Y, Liang X, Li X, Tao Y, Wang K. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of irisneovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol 2009; 87:736-740. [PMID:18803622]
9. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251:471-476. [PMID: 9792798]
10. Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T, Hinuma S, Baba A. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 2004; 325:395-400. [PMID: 15530405]
11. Kälin RE, Kretz MP, Meyer AM, Kispert A, Heppner FL, Brandli AW. Paracrine and autocrine mechanisms of apelinsignaling govern embryonic and tumor angiogenesis. Dev Biol 2007; 305:599-614. [PMID: 17412318]
12. Tao Y, Lu Q, Jiang YR, Qian J, Wang JY, Gao L, Jonas JB. Apelin in Plasma and Vitreous and in Fibrovascular Retinal Membranes from Patients with Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci 2010; 51:4237-4242.[PMID: 20220056]
13. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U, Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48:2814-2823. [PMID: 17525217]
14. Peters S, Heiduschka P, Julien S, Bartz-Schmidt KU, Schraermeyer U. Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye. Br J Ophthalmol 2008; 92:541-544. [PMID: 18211933]
15. Julien S, Heiduschka P, Hofmeister S, Schraermeyer U. Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion. Br J Ophthalmol 2008; 92:1424-1428. [PMID: 18815425]
16. Lassota N, Prause JU, Scherfig E, Kiilgaard JF, la Cour M. Clinical and histological findings after intravitreal injection of bevacizumab (Avastin) in a porcine model of choroidal neovascularization. Acta Ophthalmol 2010; 88:300-308.[PMID: 19416113]
17. Park SP, Ahn JK. Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Clin Experiment Ophthalmol 2009; 37:490-495. [PMID: 19624346]
18. Lim TH, Bae SH, Cho YJ, Lee JH, Kim HK, Sohn YH. Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. Korean J Ophthalmol 2009; 23:188-192. [PMID: 19794946]
19. Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, Ohji M. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 2010; 51:1606-1608. [PMID: 19875666]
20. Zhang Q, Zhang J, Guan Y, Zhang S, Zhu C, Xu GT, Wang L. Suppression of retinal neovascularization by the Inos inhibitor aminoguanidine in mice of oxygen-induced retinopathy. Graefes Arch Clin Exp Ophthalmol 2009; 247:919-927. [PMID: 19301028]
21. Kim EC, Lee WS, Kim MS. The inhibitory effects of bevacizumab eye drops on NGF expression and corneal wound healing in rats. Invest Ophthalmol Vis Sci 2010;51:4569-4573. [PMID: 20393106]
22. Cox CM, D'Agostino SL, Miller MK, Heimark RL, Krieg PA. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 2006; 296:177-189. [PMID: 16750822]
23. Saint-Geniez M, Masri B, Malecaze F, Knibiehler B, Audigier Y. Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels. Mech Dev 2002; 110:183-186. [PMID: 11744380]
24. Sorli SC, Le Gonidec S, Knibiehler B, Audigier Y. Apelin is a potent activator of tumour neoangiogenesis. Oncogene 2007; 26:7692-7699. [PMID: 17563744]